Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection

被引：77

作者：

Fukao, Keita ^{[1
]}

Noshi, Takeshi ^{[1
]}

Yamamoto, Atsuko ^{[1
]}

Kitano, Mitsutaka ^{[1
]}

Ando, Yoshinori ^{[1
]}

Noda, Takahiro ^{[2
]}

Baba, Kaoru ^{[2
]}

Matsumoto, Kazumi ^{[2
]}

Higuchi, Naoko ^{[1
]}

Ikeda, Minoru ^{[1
]}

Shishido, Takao ^{[1
]}

Naito, Akira ^{[1
]}

机构：

[1] Shionogi & Co Ltd, Drug Discovery & Dis Res Lab, Osaka, Japan

[2] Shionogi Technol Adv Res Co Ltd, Osaka, Japan

来源：

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2019年 / 74卷 / 03期

关键词：

OSELTAMIVIR; ADULTS; THERAPY; T-705; HOST;

D O I：

10.1093/jac/dky462

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Objectives Baloxavir marboxil (formerly S-033188) is a first-in-class, orally available, cap-dependent endonuclease inhibitor licensed in Japan and the USA for the treatment of influenza virus infection. We evaluated the efficacy of delayed oral treatment with baloxavir marboxil in combination with a neuraminidase inhibitor in a mouse model of lethal influenza virus infection. Methods The inhibitory potency of baloxavir acid (the active form of baloxavir marboxil) in combination with neuraminidase inhibitors was tested in vitro. The therapeutic effects of baloxavir marboxil and oseltamivir phosphate, or combinations thereof, were evaluated in mice lethally infected with influenza virus A/PR/8/34; treatments started 96h post-infection. Results Combinations of baloxavir acid and neuraminidase inhibitor exhibited synergistic potency against viral replication by means of inhibition of cytopathic effects in vitro. In mice, baloxavir marboxil monotherapy (15 or 50mg/kg twice daily) significantly and dose-dependently reduced virus titre 24h after administration and completely prevented mortality, whereas oseltamivir phosphate treatments were not as effective. In this model, a suboptimal dose of baloxavir marboxil (0.5mg/kg twice daily) in combination with oseltamivir phosphate provided additional efficacy compared with monotherapy in terms of virus-induced mortality, elevation of cytokine/chemokine levels and pathological changes in the lung. Conclusions Baloxavir marboxil monotherapy with 96h-delayed oral dosing achieved drastic reductions in virus titre, inflammatory response and mortality in a mouse model. Combination treatment with baloxavir acid and oseltamivir acid in vitro and baloxavir marboxil and oseltamivir phosphate in mice produced synergistic responses against influenza virus infections, suggesting that treating humans with the combination may be beneficial.

引用

页码：654 / 662

页数：9

共 39 条

[1] QUANTITATIVE-ANALYSIS OF DOSE-EFFECT RELATIONSHIPS - THE COMBINED EFFECTS OF MULTIPLE-DRUGS OR ENZYME-INHIBITORS [J].

CHOU, TC ;

TALALAY, P .

ADVANCES IN ENZYME REGULATION, 1984, 22 :27-55

[2] Structural and Biochemical Basis for Development of Influenza Virus Inhibitors Targeting the PA Endonuclease [J].

DuBois, Rebecca M. ;

Slavish, P. Jake ;

Baughman, Brandi M. ;

Yun, Mi-Kyung ;

Bao, Ju ;

Webby, Richard J. ;

Webb, Thomas R. ;

White, Stephen W. .

PLOS PATHOGENS, 2012, 8 (08)

[3] Efficacy of Oseltamivir-Zanamivir Combination Compared to Each Monotherapy for Seasonal Influenza: A Randomized Placebo-Controlled Trial [J].

Duval, Xavier ;

van der Werf, Sylvie ;

Blanchon, Thierry ;

Mosnier, Anne ;

Bouscambert-Duchamp, Maude ;

Tibi, Annick ;

Enouf, Vincent ;

Charlois-Ou, Cecile ;

Vincent, Corine ;

Andreoletti, Laurent ;

Tubach, Florence ;

Lina, Bruno ;

Mentre, France ;

Leport, Catherine .

PLOS MEDICINE, 2010, 7 (11)

[4] Oseltamivir Dosing in Critically Ill Patients With Severe Influenza [J].

Flannery, Alexander H. ;

Bastin, Melissa L. Thompson .

ANNALS OF PHARMACOTHERAPY, 2014, 48 (08) :1011-1018

[5]

Fukao K, 2017, 27 ECCMID VIENN AUST

[6] Influenza A Strain-Dependent Pathogenesis in Fatal H1N1 and H5N1 Subtype Infections of Mice [J].

Garigliany, Mutien-Marie ;

Habyarimana, Adelite ;

Lambrecht, Benedicte ;

Van de Paar, Els ;

Cornet, Anne ;

van den Berg, Thierry ;

Desmecht, Daniel .

EMERGING INFECTIOUS DISEASES, 2010, 16 (04) :595-603

[7] Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents [J].

Hayden, Frederick G. ;

Sugaya, Norio ;

Hirotsu, Nobuo ;

Lee, Nelson ;

de Jong, Menno D. ;

Hurt, Aeron C. ;

Ishida, Tadashi ;

Sekino, Hisakuni ;

Yamada, Kota ;

Portsmouth, Simon ;

Kawaguchi, Keiko ;

Shishido, Takao ;

Arai, Masatsugu ;

Tsuchiya, Kenji ;

Uehara, Takeki ;

Watanabe, Akira .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (10) :913-923

[8] Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments [J].

Heneghan, Carl J. ;

Onakpoya, Igho ;

Thompson, Matthew ;

Spencer, Elizabeth A. ;

Jones, Mark ;

Jefferson, Tom .

BMJ-BRITISH MEDICAL JOURNAL, 2014, 348

[9] Finding the right combination antiviral therapy for influenza [J].

Ison, Michael G. .

LANCET INFECTIOUS DISEASES, 2017, 17 (12) :1221-1222

[10] Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments [J].

Jefferson, Tom ;

Jones, Mark ;

Doshi, Peter ;

Spencer, Elizabeth A. ;

Onakpoya, Igho ;

Heneghan, Carl J. .

BMJ-BRITISH MEDICAL JOURNAL, 2014, 348

← 1 2 3 4 →